HEADER VIRAL PROTEIN 19-JAN-23 8C89 TITLE SARS-COV-2 SPIKE IN COMPLEX WITH THE 17T2 NEUTRALIZING ANTIBODY FAB TITLE 2 FRAGMENT (LOCAL REFINEMENT OF RBD AND FAB) COMPND MOL_ID: 1; COMPND 2 MOLECULE: SPIKE PROTEIN S2'; COMPND 3 CHAIN: C; COMPND 4 ENGINEERED: YES; COMPND 5 MOL_ID: 2; COMPND 6 MOLECULE: 17T2 FAB HEAVY CHAIN; COMPND 7 CHAIN: H; COMPND 8 ENGINEERED: YES; COMPND 9 MOL_ID: 3; COMPND 10 MOLECULE: 17T2 FAB LIGHT CHAIN; COMPND 11 CHAIN: L; COMPND 12 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS; SOURCE 3 ORGANISM_TAXID: 2901879; SOURCE 4 GENE: S, 2; SOURCE 5 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 9606; SOURCE 7 EXPRESSION_SYSTEM_CELL: HEK293; SOURCE 8 MOL_ID: 2; SOURCE 9 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 10 ORGANISM_TAXID: 9606; SOURCE 11 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 12 EXPRESSION_SYSTEM_TAXID: 9606; SOURCE 13 EXPRESSION_SYSTEM_CELL: EXPI293; SOURCE 14 MOL_ID: 3; SOURCE 15 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 16 ORGANISM_TAXID: 9606; SOURCE 17 EXPRESSION_SYSTEM: HOMO SAPIENS; SOURCE 18 EXPRESSION_SYSTEM_TAXID: 9606; SOURCE 19 EXPRESSION_SYSTEM_CELL: EXPI293 KEYWDS COMPLEX SARS-COV-2 SPIKE S 17T2, VIRAL PROTEIN EXPDTA ELECTRON MICROSCOPY AUTHOR A.MODREGO,D.CARLERO,M.T.BUENO-CARRASCO,C.SANTIAGO,C.CAROLIS,R.ARRANZ, AUTHOR 2 J.BLANCO,G.MAGRI REVDAT 2 21-FEB-24 8C89 1 JRNL REVDAT 1 10-JAN-24 8C89 0 JRNL AUTH L.DE CAMPOS-MATA,B.TRINITE,A.MODREGO,S.TEJEDOR VAQUERO, JRNL AUTH 2 E.PRADENAS,A.PONS-GRIFOLS,N.RODRIGO MELERO,D.CARLERO, JRNL AUTH 3 S.MARFIL,C.SANTIAGO,D.RAICH-REGUE,M.T.BUENO-CARRASCO, JRNL AUTH 4 F.TARRES-FREIXAS,F.ABANCO,V.URREA,N.IZQUIERDO-USEROS, JRNL AUTH 5 E.RIVEIRA-MUNOZ,E.BALLANA,M.PEREZ,J.VERGARA-ALERT,J.SEGALES, JRNL AUTH 6 C.CAROLIS,R.ARRANZ,J.BLANCO,G.MAGRI JRNL TITL A MONOCLONAL ANTIBODY TARGETING A LARGE SURFACE OF THE JRNL TITL 2 RECEPTOR BINDING MOTIF SHOWS PAN-NEUTRALIZING SARS-COV-2 JRNL TITL 3 ACTIVITY. JRNL REF NAT COMMUN V. 15 1051 2024 JRNL REFN ESSN 2041-1723 JRNL PMID 38316751 JRNL DOI 10.1038/S41467-024-45171-9 REMARK 2 REMARK 2 RESOLUTION. 4.41 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 SOFTWARE PACKAGES : NULL REMARK 3 RECONSTRUCTION SCHEMA : NULL REMARK 3 REMARK 3 EM MAP-MODEL FITTING AND REFINEMENT REMARK 3 PDB ENTRY : NULL REMARK 3 REFINEMENT SPACE : NULL REMARK 3 REFINEMENT PROTOCOL : NULL REMARK 3 REFINEMENT TARGET : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE : NULL REMARK 3 REMARK 3 FITTING PROCEDURE : NULL REMARK 3 REMARK 3 EM IMAGE RECONSTRUCTION STATISTICS REMARK 3 NOMINAL PIXEL SIZE (ANGSTROMS) : NULL REMARK 3 ACTUAL PIXEL SIZE (ANGSTROMS) : NULL REMARK 3 EFFECTIVE RESOLUTION (ANGSTROMS) : 4.410 REMARK 3 NUMBER OF PARTICLES : 124570 REMARK 3 CTF CORRECTION METHOD : PHASE FLIPPING AND AMPLITUDE REMARK 3 CORRECTION REMARK 3 REMARK 3 EM RECONSTRUCTION MAGNIFICATION CALIBRATION: NULL REMARK 3 REMARK 3 OTHER DETAILS: NULL REMARK 4 REMARK 4 8C89 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 19-JAN-23. REMARK 100 THE DEPOSITION ID IS D_1292128046. REMARK 245 REMARK 245 EXPERIMENTAL DETAILS REMARK 245 RECONSTRUCTION METHOD : SINGLE PARTICLE REMARK 245 SPECIMEN TYPE : NULL REMARK 245 REMARK 245 ELECTRON MICROSCOPE SAMPLE REMARK 245 SAMPLE TYPE : PARTICLE REMARK 245 PARTICLE TYPE : POINT REMARK 245 NAME OF SAMPLE : SARS-COV-2 OMICRON VARIANT REMARK 245 SPIKE TRIMER IN COMPLEX WITH REMARK 245 THREE 17T2 FABS; SPIKE REMARK 245 GLYCOPROTEIN RBD; 17T2 FAB REMARK 245 SAMPLE CONCENTRATION (MG ML-1) : NULL REMARK 245 SAMPLE SUPPORT DETAILS : NULL REMARK 245 SAMPLE VITRIFICATION DETAILS : NULL REMARK 245 SAMPLE BUFFER : NULL REMARK 245 PH : 7.60 REMARK 245 SAMPLE DETAILS : NULL REMARK 245 REMARK 245 DATA ACQUISITION REMARK 245 DATE OF EXPERIMENT : NULL REMARK 245 NUMBER OF MICROGRAPHS-IMAGES : NULL REMARK 245 TEMPERATURE (KELVIN) : NULL REMARK 245 MICROSCOPE MODEL : TFS TALOS F200C REMARK 245 DETECTOR TYPE : FEI FALCON III (4K X 4K) REMARK 245 MINIMUM DEFOCUS (NM) : 1000.00 REMARK 245 MAXIMUM DEFOCUS (NM) : 2500.00 REMARK 245 MINIMUM TILT ANGLE (DEGREES) : NULL REMARK 245 MAXIMUM TILT ANGLE (DEGREES) : NULL REMARK 245 NOMINAL CS : NULL REMARK 245 IMAGING MODE : BRIGHT FIELD REMARK 245 ELECTRON DOSE (ELECTRONS NM**-2) : 3200.00 REMARK 245 ILLUMINATION MODE : OTHER REMARK 245 NOMINAL MAGNIFICATION : NULL REMARK 245 CALIBRATED MAGNIFICATION : NULL REMARK 245 SOURCE : FIELD EMISSION GUN REMARK 245 ACCELERATION VOLTAGE (KV) : 200 REMARK 245 IMAGING DETAILS : NULL REMARK 247 REMARK 247 ELECTRON MICROSCOPY REMARK 247 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM ELECTRON REMARK 247 MICROSCOPY DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE REMARK 247 THAT CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES REMARK 247 ON THESE RECORDS ARE MEANINGLESS EXCEPT FOR THE CALCULATION REMARK 247 OF THE STRUCTURE FACTORS. REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 6330 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 30880 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -21.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, H, L, A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OG SER H 17 OE1 GLU H 82 2.15 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ARG L 110 CG - CD - NE ANGL. DEV. = 13.1 DEGREES REMARK 500 ARG L 110 NE - CZ - NH1 ANGL. DEV. = 3.2 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR C 333 -123.24 65.69 REMARK 500 ALA C 352 -168.62 -127.23 REMARK 500 CYS C 361 -175.66 -171.81 REMARK 500 ASP C 364 30.31 -84.71 REMARK 500 ASN C 439 -100.05 59.01 REMARK 500 PHE C 456 -176.39 -177.29 REMARK 500 ASN C 481 -76.25 67.06 REMARK 500 GLN H 35 -179.40 -170.93 REMARK 500 LEU H 45 93.77 -69.63 REMARK 500 GLN H 62 20.74 47.97 REMARK 500 THR H 126 122.59 -22.11 REMARK 500 PRO H 157 -146.73 -81.86 REMARK 500 GLU H 158 163.66 -47.76 REMARK 500 PRO H 177 -174.29 -64.22 REMARK 500 SER H 182 132.73 66.03 REMARK 500 PRO L 8 80.20 -62.47 REMARK 500 ALA L 52 -128.78 53.59 REMARK 500 SER L 53 -70.22 -66.97 REMARK 500 SER L 54 65.53 39.57 REMARK 500 ASP L 61 -4.73 -58.55 REMARK 500 ASN L 140 53.38 37.74 REMARK 500 ASN L 160 51.59 -91.71 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 VAL H 34 GLN H 35 141.04 REMARK 500 CYS H 101 ASN H 102 142.12 REMARK 500 GLU H 158 PRO H 159 -146.25 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: PLANAR GROUPS REMARK 500 REMARK 500 PLANAR GROUPS IN THE FOLLOWING RESIDUES HAVE A TOTAL REMARK 500 RMS DISTANCE OF ALL ATOMS FROM THE BEST-FIT PLANE REMARK 500 BY MORE THAN AN EXPECTED VALUE OF 6*RMSD, WITH AN REMARK 500 RMSD 0.02 ANGSTROMS, OR AT LEAST ONE ATOM HAS REMARK 500 AN RMSD GREATER THAN THIS VALUE REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI RMS TYPE REMARK 500 ARG L 110 0.10 SIDE CHAIN REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: EMD-16473 RELATED DB: EMDB REMARK 900 SARS-COV-2 SPIKE IN COMPLEX WITH THE 17T2 NEUTRALIZING ANTIBODY FAB REMARK 900 FRAGMENT (LOCAL REFINEMENT OF RBD AND FAB) DBREF 8C89 C 324 533 UNP P0DTC2 SPIKE_SARS2 324 533 DBREF 8C89 H 1 226 PDB 8C89 8C89 1 226 DBREF 8C89 L 1 216 PDB 8C89 8C89 1 216 SEQADV 8C89 ASP C 339 UNP P0DTC2 GLY 339 VARIANT SEQADV 8C89 LEU C 371 UNP P0DTC2 SER 371 VARIANT SEQADV 8C89 PRO C 373 UNP P0DTC2 SER 373 VARIANT SEQADV 8C89 PHE C 375 UNP P0DTC2 SER 375 VARIANT SEQADV 8C89 ASN C 417 UNP P0DTC2 LYS 417 VARIANT SEQADV 8C89 LYS C 440 UNP P0DTC2 ASN 440 VARIANT SEQADV 8C89 SER C 446 UNP P0DTC2 GLY 446 VARIANT SEQADV 8C89 ASN C 477 UNP P0DTC2 SER 477 VARIANT SEQADV 8C89 LYS C 478 UNP P0DTC2 THR 478 VARIANT SEQADV 8C89 ALA C 484 UNP P0DTC2 GLU 484 VARIANT SEQADV 8C89 ARG C 493 UNP P0DTC2 GLN 493 VARIANT SEQADV 8C89 SER C 496 UNP P0DTC2 GLY 496 VARIANT SEQADV 8C89 ARG C 498 UNP P0DTC2 GLN 498 VARIANT SEQADV 8C89 TYR C 501 UNP P0DTC2 ASN 501 VARIANT SEQADV 8C89 HIS C 505 UNP P0DTC2 TYR 505 VARIANT SEQRES 1 C 210 GLU SER ILE VAL ARG PHE PRO ASN ILE THR ASN LEU CYS SEQRES 2 C 210 PRO PHE ASP GLU VAL PHE ASN ALA THR ARG PHE ALA SER SEQRES 3 C 210 VAL TYR ALA TRP ASN ARG LYS ARG ILE SER ASN CYS VAL SEQRES 4 C 210 ALA ASP TYR SER VAL LEU TYR ASN LEU ALA PRO PHE PHE SEQRES 5 C 210 THR PHE LYS CYS TYR GLY VAL SER PRO THR LYS LEU ASN SEQRES 6 C 210 ASP LEU CYS PHE THR ASN VAL TYR ALA ASP SER PHE VAL SEQRES 7 C 210 ILE ARG GLY ASP GLU VAL ARG GLN ILE ALA PRO GLY GLN SEQRES 8 C 210 THR GLY ASN ILE ALA ASP TYR ASN TYR LYS LEU PRO ASP SEQRES 9 C 210 ASP PHE THR GLY CYS VAL ILE ALA TRP ASN SER ASN LYS SEQRES 10 C 210 LEU ASP SER LYS VAL SER GLY ASN TYR ASN TYR LEU TYR SEQRES 11 C 210 ARG LEU PHE ARG LYS SER ASN LEU LYS PRO PHE GLU ARG SEQRES 12 C 210 ASP ILE SER THR GLU ILE TYR GLN ALA GLY ASN LYS PRO SEQRES 13 C 210 CYS ASN GLY VAL ALA GLY PHE ASN CYS TYR PHE PRO LEU SEQRES 14 C 210 ARG SER TYR SER PHE ARG PRO THR TYR GLY VAL GLY HIS SEQRES 15 C 210 GLN PRO TYR ARG VAL VAL VAL LEU SER PHE GLU LEU LEU SEQRES 16 C 210 HIS ALA PRO ALA THR VAL CYS GLY PRO LYS LYS SER THR SEQRES 17 C 210 ASN LEU SEQRES 1 H 226 GLN VAL GLN LEU VAL GLN SER GLY PRO GLU VAL LYS LYS SEQRES 2 H 226 PRO GLY THR SER VAL LYS VAL SER CYS LYS ALA PRO VAL SEQRES 3 H 226 PHE THR PHE SER ILE SER ALA VAL GLN TRP VAL ARG GLN SEQRES 4 H 226 ALA ARG GLY GLN ARG LEU GLU TRP ILE GLY TRP ILE VAL SEQRES 5 H 226 VAL GLY SER GLY ASN THR ASN TYR ALA GLN ASN PHE GLN SEQRES 6 H 226 GLU ARG VAL THR ILE THR THR ASP MET SER THR GLY THR SEQRES 7 H 226 VAL TYR MET GLU LEU SER GLY LEU ARG SER GLU ASP THR SEQRES 8 H 226 ALA MET TYR TYR CYS ALA ALA PRO TYR CYS ASN ARG THR SEQRES 9 H 226 THR CYS TYR ASP GLY PHE ASP LEU TRP GLY GLN GLY THR SEQRES 10 H 226 MET VAL THR VAL SER SER ALA SER THR LYS GLY PRO SER SEQRES 11 H 226 VAL PHE PRO LEU ALA PRO SER SER LYS SER THR SER GLY SEQRES 12 H 226 GLY THR ALA ALA LEU GLY CYS LEU VAL LYS ASP TYR PHE SEQRES 13 H 226 PRO GLU PRO VAL THR VAL SER TRP ASN SER GLY ALA LEU SEQRES 14 H 226 THR SER GLY VAL HIS THR PHE PRO ALA VAL LEU GLN SER SEQRES 15 H 226 SER GLY LEU TYR SER LEU SER SER VAL VAL THR VAL PRO SEQRES 16 H 226 SER SER SER LEU GLY THR GLN THR TYR ILE CYS ASN VAL SEQRES 17 H 226 ASN HIS LYS PRO SER ASN THR LYS VAL ASP LYS ARG VAL SEQRES 18 H 226 GLU PRO LYS SER CYS SEQRES 1 L 216 GLU ILE VAL LEU THR GLN SER PRO GLY THR LEU SER LEU SEQRES 2 L 216 SER PRO GLY GLU ARG ALA THR LEU SER CYS ARG ALA SER SEQRES 3 L 216 GLN SER ILE SER SER ASN TYR LEU ALA TRP TYR GLN GLN SEQRES 4 L 216 LYS PRO GLY GLN ALA PRO ARG LEU LEU ILE TYR GLY ALA SEQRES 5 L 216 SER SER ARG ALA THR GLY ILE PRO ASP ARG PHE SER GLY SEQRES 6 L 216 SER GLY SER GLY THR ASP PHE THR LEU SER ILE ASN ARG SEQRES 7 L 216 LEU GLU PRO GLU ASP PHE ALA MET TYR TYR CYS GLN HIS SEQRES 8 L 216 TYR GLY GLY LEU SER ARG TRP THR PHE GLY GLN GLY THR SEQRES 9 L 216 LYS VAL GLU ILE LYS ARG THR VAL ALA ALA PRO SER VAL SEQRES 10 L 216 PHE ILE PHE PRO PRO SER ASP GLU GLN LEU LYS SER GLY SEQRES 11 L 216 THR ALA SER VAL VAL CYS LEU LEU ASN ASN PHE TYR PRO SEQRES 12 L 216 ARG GLU ALA LYS VAL GLN TRP LYS VAL ASP ASN ALA LEU SEQRES 13 L 216 GLN SER GLY ASN SER GLN GLU SER VAL THR GLU GLN ASP SEQRES 14 L 216 SER LYS ASP SER THR TYR SER LEU SER SER THR LEU THR SEQRES 15 L 216 LEU SER LYS ALA ASP TYR GLU LYS HIS LYS VAL TYR ALA SEQRES 16 L 216 CYS GLU VAL THR HIS GLN GLY LEU SER SER PRO VAL THR SEQRES 17 L 216 LYS SER PHE ASN ARG GLY GLU CYS HET NAG A 1 14 HET NAG A 2 14 HET NAG B 1 14 HET NAG B 2 14 HETNAM NAG 2-ACETAMIDO-2-DEOXY-BETA-D-GLUCOPYRANOSE HETSYN NAG N-ACETYL-BETA-D-GLUCOSAMINE; 2-ACETAMIDO-2-DEOXY-BETA- HETSYN 2 NAG D-GLUCOSE; 2-ACETAMIDO-2-DEOXY-D-GLUCOSE; 2-ACETAMIDO- HETSYN 3 NAG 2-DEOXY-GLUCOSE; N-ACETYL-D-GLUCOSAMINE FORMUL 4 NAG 4(C8 H15 N O6) HELIX 1 AA1 PHE C 338 ASN C 343 1 6 HELIX 2 AA2 THR C 385 ASP C 389 5 5 HELIX 3 AA3 ARG C 403 ILE C 410 5 8 HELIX 4 AA4 ASN C 417 ASN C 422 1 6 HELIX 5 AA5 ARG H 87 THR H 91 5 5 HELIX 6 AA6 SER H 137 GLY H 143 5 7 HELIX 7 AA7 SER H 197 LEU H 199 5 3 HELIX 8 AA8 GLU L 80 PHE L 84 5 5 HELIX 9 AA9 SER L 123 SER L 129 1 7 HELIX 10 AB1 LYS L 185 HIS L 191 1 7 SHEET 1 AA1 5 LYS C 356 ARG C 357 0 SHEET 2 AA1 5 TYR C 396 ILE C 402 -1 O ALA C 397 N LYS C 356 SHEET 3 AA1 5 TYR C 508 SER C 514 -1 O SER C 514 N TYR C 396 SHEET 4 AA1 5 CYS C 432 ASN C 437 -1 N TRP C 436 O ARG C 509 SHEET 5 AA1 5 PHE C 375 CYS C 379 -1 N LYS C 378 O VAL C 433 SHEET 1 AA2 2 CYS C 361 VAL C 362 0 SHEET 2 AA2 2 VAL C 524 CYS C 525 1 O CYS C 525 N CYS C 361 SHEET 1 AA3 2 LEU C 452 ARG C 454 0 SHEET 2 AA3 2 LEU C 492 SER C 494 -1 O ARG C 493 N TYR C 453 SHEET 1 AA4 3 VAL H 5 GLN H 6 0 SHEET 2 AA4 3 CYS H 22 LYS H 23 -1 O LYS H 23 N VAL H 5 SHEET 3 AA4 3 THR H 78 VAL H 79 -1 O VAL H 79 N CYS H 22 SHEET 1 AA5 5 GLU H 10 VAL H 11 0 SHEET 2 AA5 5 THR H 117 THR H 120 1 O THR H 120 N GLU H 10 SHEET 3 AA5 5 ALA H 92 ALA H 98 -1 N TYR H 94 O THR H 117 SHEET 4 AA5 5 ALA H 33 GLN H 39 -1 N GLN H 39 O MET H 93 SHEET 5 AA5 5 ILE H 51 VAL H 52 -1 O ILE H 51 N VAL H 34 SHEET 1 AA6 4 GLU H 46 TRP H 47 0 SHEET 2 AA6 4 ALA H 33 GLN H 39 -1 N ARG H 38 O GLU H 46 SHEET 3 AA6 4 ALA H 92 ALA H 98 -1 O MET H 93 N GLN H 39 SHEET 4 AA6 4 LEU H 112 TRP H 113 -1 O LEU H 112 N ALA H 98 SHEET 1 AA7 3 VAL H 18 LYS H 19 0 SHEET 2 AA7 3 GLU H 82 LEU H 83 -1 O LEU H 83 N VAL H 18 SHEET 3 AA7 3 VAL H 68 THR H 69 -1 N THR H 69 O GLU H 82 SHEET 1 AA8 4 SER H 130 LEU H 134 0 SHEET 2 AA8 4 THR H 145 TYR H 155 -1 O GLY H 149 N LEU H 134 SHEET 3 AA8 4 TYR H 186 PRO H 195 -1 O LEU H 188 N VAL H 152 SHEET 4 AA8 4 VAL H 173 THR H 175 -1 N HIS H 174 O VAL H 191 SHEET 1 AA9 3 THR H 161 TRP H 164 0 SHEET 2 AA9 3 ILE H 205 HIS H 210 -1 O ASN H 207 N SER H 163 SHEET 3 AA9 3 THR H 215 ARG H 220 -1 O LYS H 219 N CYS H 206 SHEET 1 AB1 2 LEU L 11 LEU L 13 0 SHEET 2 AB1 2 VAL L 106 ILE L 108 1 O GLU L 107 N LEU L 11 SHEET 1 AB2 3 ALA L 19 SER L 22 0 SHEET 2 AB2 3 ASP L 71 ILE L 76 -1 O LEU L 74 N LEU L 21 SHEET 3 AB2 3 GLY L 67 SER L 68 -1 N SER L 68 O ASP L 71 SHEET 1 AB3 3 ARG L 46 LEU L 47 0 SHEET 2 AB3 3 LEU L 34 GLN L 39 -1 N GLN L 38 O ARG L 46 SHEET 3 AB3 3 MET L 86 HIS L 91 -1 O TYR L 88 N TYR L 37 SHEET 1 AB4 4 PHE L 118 PHE L 120 0 SHEET 2 AB4 4 THR L 131 PHE L 141 -1 O LEU L 137 N PHE L 118 SHEET 3 AB4 4 TYR L 175 SER L 184 -1 O LEU L 177 N LEU L 138 SHEET 4 AB4 4 GLN L 162 THR L 166 -1 N THR L 166 O SER L 176 SHEET 1 AB5 4 ALA L 155 GLN L 157 0 SHEET 2 AB5 4 LYS L 147 VAL L 152 -1 N VAL L 152 O ALA L 155 SHEET 3 AB5 4 VAL L 193 HIS L 200 -1 O GLU L 197 N GLN L 149 SHEET 4 AB5 4 LEU L 203 ASN L 212 -1 O VAL L 207 N VAL L 198 SSBOND 1 CYS C 336 CYS C 361 1555 1555 2.02 SSBOND 2 CYS C 379 CYS C 432 1555 1555 2.03 SSBOND 3 CYS C 391 CYS C 525 1555 1555 2.04 SSBOND 4 CYS C 480 CYS C 488 1555 1555 2.03 SSBOND 5 CYS H 22 CYS H 96 1555 1555 2.04 SSBOND 6 CYS H 101 CYS H 106 1555 1555 2.04 SSBOND 7 CYS H 150 CYS H 206 1555 1555 2.05 SSBOND 8 CYS L 23 CYS L 89 1555 1555 2.05 SSBOND 9 CYS L 136 CYS L 196 1555 1555 2.04 LINK ND2 ASN C 343 C1 NAG A 1 1555 1555 1.46 LINK ND2 ASN H 102 C1 NAG B 1 1555 1555 1.42 LINK O4 NAG A 1 C1 NAG A 2 1555 1555 1.44 LINK O4 NAG B 1 C1 NAG B 2 1555 1555 1.44 CISPEP 1 SER H 123 ALA H 124 0 4.12 CISPEP 2 PHE H 156 PRO H 157 0 -9.94 CISPEP 3 TYR L 142 PRO L 143 0 -0.44 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000